CAMBRIDGE, England, June 27, 2022 /PRNewswire/ — Abcam plc (“Abcam,” “Corporation,” “Group”) (Intention: ABC) (Nasdaq: ABCM), a world chief in the supply of existence science investigate tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.
Tommy, who will be based mostly in our Waltham, MA business, has above 20 years’ knowledge in the daily life sciences sector, largely targeted in the region of research equipment. He joins Abcam from Avantor, wherever he was Vice President, Investor Relations for various many years. Prior to this he was Vice President of Investor Relations, and then Main Monetary Officer of Global Providers at Perkin Elmer. In advance of becoming a member of Perkin Elmer, Tommy put in eight decades as a get facet analyst for TIAA-CREF targeted on the health-related technological innovation & daily life science instruments spots.
Michael Baldock, Main Fiscal Officer of Abcam, mentioned: “I am delighted to have Tommy signing up for us. His deep sector working experience, major trader relations abilities, and potent institutional investor and investigation analyst associations are a important stage forward for us. Tommy will be a true asset to Abcam and our investors as we carry on to expand, differentiate ourselves in the marketplace, and supply value for all our stakeholders.”
Tommy Thomas commented: “I am extremely delighted to be part of Abcam at this essential time in its evolution. The Company’s customer-centric product concentrating on new product innovation for scientists and clinicians in the everyday living sciences field is really differentiated. I glimpse ahead to understanding and telling our tale as I construct new friendships alongside the way.”
About Abcam plc
As an innovator in reagents and instruments, Abcam’s reason is to provide daily life science researchers globally to realize their mission, speedier. Furnishing the research and clinical communities with instruments and scientific aid, the Corporation features remarkably validated antibodies, assays and other study equipment to handle vital targets in significant organic pathways.
Currently a pioneer in details sharing and ecommerce in the everyday living sciences, Abcam’s ambition is to be the most influential organization in life sciences by supporting progress worldwide knowing of biology and causes of disease, which, in switch, will push new solutions and improved overall health.
Abcam’s around the globe purchaser base of roughly 750,000 life science researchers employs Abcam’s antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these scientists, the Enterprise repeatedly advances its portfolio to tackle their desires. A clear programme of customer opinions and datasheets, blended with an business-leading validation initiative, provides researchers amplified self confidence in their final results.
Started in 1998 and headquartered in Cambridge, United kingdom, the Business has served consumers in far more than 130 countries. Abcam’s everyday shares are stated on the London Stock Trade (Aim: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq World Market place (Nasdaq: ABCM).
Please visit corporate.abcam.com to uncover out a lot more.
Supply Abcam plc